|
Patent landscape, scope, and claims: |
Scope and claims analysis of U.S. Patent 10,584,113 (methylphenidate unconjugated vs conjugated composition)
Executive summary: U.S. Patent 10,584,113 is directed to an oral (and broad dosage-form) composition that combines (i) unconjugated d-threo-methylphenidate with (ii) a conjugated d-methylphenidate prodrug/“compound” of a defined chemical structure, optionally as pharmaceutically acceptable salts, with claims focused on salt selection, dosing ranges (molar equivalent), dose ranges per unit, and ratios/weights of unconjugated vs conjugated d-methylphenidate active. The claim set is structurally broad (many salts and dosage forms) but functionally narrow on one core element: the conjugated methylphenidate “compound” must be the specific conjugate defined by the patent’s chemical structure(s). Any third-party composition that changes the conjugate structure (or avoids the unconjugated/conjugated combination) is the primary freedom-to-operate fault line.
What is claimed in U.S. Patent 10,584,113? (composition of unconjugated d-threo-methylphenidate plus conjugate prodrug)
Core independent claim (Claim 1)
- A composition comprising:
- Unconjugated methylphenidate, wherein the unconjugated methylphenidate is d-threo-methylphenidate,
- At least one pharmaceutically acceptable salt of the unconjugated d-threo-methylphenidate (or mixtures),
- And a compound that is a conjugate of d-methylphenidate, defined by the patent as having “the following chemical formula” and further followed by salt language.
Practical scope of Claim 1
- “Unconjugated” anchors the active to the free base/typical methylphenidate form (stated as d-threo-methylphenidate).
- “Conjugate of d-methylphenidate” requires the presence of a specific prodrug/conjugate entity defined by the patent’s formula (the prompt omits the formula in places; the claims still require it).
- Combination composition is the key: the claim covers formulations that contain both the unconjugated d-threo-methylphenidate and the conjugated d-methylphenidate compound within the same dosage form.
- Salt flexibility is extensive. The salt of either component can be “at least one pharmaceutically acceptable salt” (with downstream claims listing example salts).
What is the “conjugate” element likely to control legally?
- Independent claim 1 makes infringement hinge on whether the accused product contains the defined conjugated d-methylphenidate compound (or a salt/mixture thereof).
- Even if an accused product uses d-threo-methylphenidate plus a different methylphenidate prodrug, it will generally miss the claim unless the substitute prodrug falls within the claim’s chemical formula.
Which salts are covered for unconjugated d-threo-methylphenidate and the conjugated compound?
Salt coverage in Claim 2 (broad list)
Claim 2 expands Claim 1 by specifying that the pharmaceutically acceptable salts of the unconjugated methylphenidate and/or the compound are selected from a long enumerated group, including:
- Common inorganic/organic acid salts: acetate, citrate, fumarate, hydrochloride, hydrobromide, mesylate, phosphate, succinate, sulfate, tartrate (plus multiple isomeric/di-tartrate forms),
- Sulfonates and other specialty salts: benzenesulfonate (spelled elsewhere as benzene sulfonate), besylate, edisylate, tosylate, camsylate, camesylate (spelling variants in the prompt text), pamoate, thiocyanate, etc.
- Numerous additional salts including: oxalate, maleate, malonate, nicotinate, nitrate, orotate, propionate, salicylate, stearate, xinafoate, and others.
The list is large enough that a competitor using most standard salt selections is likely within the salt genus.
Claim 3 narrows (still broad)
Claim 3 further specifies a (smaller) enumerated subset of salts, including:
- chloride, hydrogen carbonate (bicarbonate), iodide, bromide, citrate, acetate, formate, salicylate, bisulfate, hydroxide, nitrate, bisulfite, propionate, benzene sulfonate, hypophosphite, phosphate, bromate, iodate, chlorate, fluoride, nitrite, and combinations.
Claim 4 locks a specific unconjugated salt
- Claim 4 states the pharmaceutically acceptable salt of the unconjugated methylphenidate is d-threo-methylphenidate hydrochloride.
Claim 6 references a further salt condition
- Claim 6 adds: further comprising a pharmaceutically acceptable salt of the unconjugated methylphenidate, wherein the salt is d-threo-methylphenidate hydrochloride.
Legal takeaway
- The patent is structured so that broad Claim 1 already covers “at least one pharmaceutically acceptable salt,” with Claims 2-4 layering enumerated salt sets and a specific hydrochloride variant. This creates a high chance of coverage across standard salt forms, unless a competitor chooses a salt outside the enumerated examples and argues it is not “pharmaceutically acceptable” for the purposes of the claim.
What dosage forms are covered (tablets, OTF strips, gummies, suppositories)?
Claim 7 (dosage-form breadth)
The composition of Claim 1 is in a dosage form selected from:
- sublingual
- gummy
- chewable tablet
- rapidly dissolving tablet
- tablet
- capsule
- caplet
- troche
- lozenge
- oral powder
- solution
- thin strip
- oral thin film (OTF)
- oral strip
- rectal film
- syrup
- suspension
- suppository
Legal takeaway
- This is not limited to an extended-release matrix, osmotic pump, beads, or any specific delivery technology.
- If the dosage form contains the claimed actives (unconjugated d-threo-methylphenidate plus the claimed conjugate compound), form factor alone likely won’t provide a design-around.
What dosing ranges are claimed (molar equivalent to d-methylphenidate HCl per dose)?
Claim 8 (outer dosing band)
- Dose amount is a molar equivalent to 0.1 mg to 500 mg of d-methylphenidate hydrochloride per dose.
Dependent claims carve narrower windows
- Claim 9: 1–400 mg
- Claim 10: 1–300 mg
- Claim 11: 1–250 mg
- Claim 12: 2–200 mg
- Claim 13: 5–150 mg
- Claim 14: 10–100 mg
- Claim 15: 20–80 mg
Claims 16-17 tie to unit-dose size
- Claim 16: unit dose form, blister pack, roll, or bulk bottle.
- Claim 17: unit dose provides 0.5–500 mg (molar equivalent) of d-methylphenidate hydrochloride.
Legal takeaway
- This claim architecture creates multiple “infringement entry points” since many real-world dosage strengths fall inside these windows.
- Design-around by dosing alone is unlikely to avoid all dependent ranges unless the competitor places the product outside every recited band (which would be a commercial constraint).
How is the conjugate used with unconjugated methylphenidate (combined dose and ratio claims)?
Claim 18 (combined therapeutically effective dose)
- The composition comprises:
- (a) a pharmaceutically acceptable salt of unconjugated methylphenidate, where the salt is d-threo-methylphenidate hydrochloride, and
- (b) a pharmaceutically acceptable salt of the conjugate compound having a defined structure.
This explicitly requires both components in the combined therapeutically effective dose.
Claims 19–21 (weight ratio ranges)
Claim 19:
- unconjugated contributes 5% to 95% by weight (based on total weight of d-methylphenidate active),
- conjugated contributes 95% to 5% by weight.
Claim 20:
- unconjugated 10% and conjugated 90% range (unconjugated 10% by weight, conjugated 90% by weight).
Claim 21:
- unconjugated 30% and conjugated 70% by weight.
Claims 22 (specific discrete mg quantities)
Claim 22 lists specific molar equivalent amounts (non-exclusive list) for unconjugated d-threo-methylphenidate active and corresponding conjugated d-threo-methylphenidate active amounts, e.g.:
- Unconjugated: 1.3 mg, 2 mg, 2.6 mg, … 20.8 mg
- Conjugated: 6.5 mg, 13.1 mg, 19.6 mg, … 140 mg
This creates multiple exact “sweet spots” where infringement could be found even if weight-based ranges are ambiguous.
Legal takeaway
- The patent is not limited to a single fixed blend. It covers:
- broad percentage ranges (Claim 19),
- specific ratio examples (Claims 20 and 21),
- and multiple discrete dose pairings (Claim 22).
- A competitor would need to avoid the specific blend logic or eliminate one component.
What excipients are covered (and can the product include other APIs)?
Claim 23
- Composition further comprises one or more excipients or one or more additional pharmaceutically active ingredients.
Claim 24
- Excipients are selected from a group including:
- anti-adherents, binders, coatings, disintegrants, gel-forming agents, fillers, flavors, colorants,
- glidants, lubricants, preservatives, sorbents, sweeteners.
Legal takeaway
- The patent is not an excipient-limited formulation claim.
- Co-formulation with other actives does not avoid infringement if the claimed methylphenidate/unconjugated+conjugate structure and dosing/ratio requirements are met.
Where does infringement most likely occur (claim mapping priorities)?
- Claim 1 element test (most decisive)
- Presence of d-threo-methylphenidate as unconjugated active
- Presence of the specified conjugate of d-methylphenidate (the “compound” defined by formula)
- Salt form is not a strong escape route due to broad “pharmaceutically acceptable salt” coverage.
- Then check dosage/ratio dependencies
- If a product’s per-dose molar equivalent of d-methylphenidate HCl falls within 0.1–500 mg (and often within nested dependent windows), it fits the dosing architecture.
- If the unconjugated-to-conjugated contribution to total d-methylphenidate active is within the broad 5–95 weight range (and likely within example ranges), the ratio claims become additional risk.
- Dosage form does not materially narrow scope
- OTF/films, gummies, chewables, tablets, capsules, solutions, suspensions, and suppositories are all included.
How does this patent compare with typical methylphenidate competitive strategies?
Common design-around levers in methylphenidate prodrug landscapes
- Avoid the conjugate structure: use a different prodrug or delivery approach not encompassed by the claimed chemical formula.
- Avoid the combination: use only unconjugated d-threo-methylphenidate (standard salts) without the conjugate.
- Avoid the specific dose/ratio windows: keep dose outside all recited molar-equivalent and blend ranges, though the claims are broad and include many example discrete pairs.
Given this claim set:
- Salt switching is unlikely to create a meaningful gap because salts are extensively enumerated and also covered by the generic “pharmaceutically acceptable salt” language.
- Changing dosage form is also unlikely because Claim 7 is wide.
- Primary gap remains the identity of the conjugated d-methylphenidate compound.
Patent landscape items that are typically adjacent to U.S. Patent 10,584,113 (what to look for in prosecution and continuation families)
Because the prompt provides only claim text, the landscape below is limited to scope-inference based on how this claim set is drafted.
Likely related patent categories inside the same family
- Specific conjugate synthesis intermediates and salts: claims typically include “compound having formula” and salt embodiments.
- Formulation and unit-dose claims: dependent claims often cover dose strengths and delivery systems, including OTF, chewables, capsules, and solutions.
- Ratio and dosing claims: the mg and weight percent constraints suggest the applicant sought coverage across multiple blend configurations, not a single formulation.
Litigation and regulatory posture
- Without Orange Book entry data, FDA labeling, and PTAB/court docket history for 10,584,113, no credible enforcement timelines can be set from the prompt alone.
(Per operating constraints, no additional unverifiable specifics are included.)
Key Takeaways
- U.S. Patent 10,584,113 claims a two-component methylphenidate composition: unconjugated d-threo-methylphenidate plus a specific conjugated d-methylphenidate compound defined by the patent’s chemical formula.
- The claim scope is broad on salts and dosage forms (many salt enumerations; tablets/capsules/OTF/gummies/solutions/suspensions/suppositories).
- The claim scope is narrow on the conjugate identity: infringement depends on the conjugate matching the claimed formula.
- Multiple dependent layers increase infringement probability:
- per-dose molar equivalent windows (nested ranges from 0.1–500 mg),
- weight ratio of unconjugated vs conjugated active (5–95%; plus example 10/90 and 30/70),
- and specific mg pairings (Claim 22).
- The patent is compatible with other excipients and even additional active ingredients, so product complexity is not a designed escape route.
FAQs
-
Does U.S. Patent 10,584,113 cover methylphenidate hydrochloride alone without the conjugated compound?
The claims require both unconjugated d-threo-methylphenidate and the specified conjugate compound in the same composition (Claim 1 and Claim 18).
-
Can a competitor avoid infringement by changing only the salt form?
The patent covers extensive pharmaceutically acceptable salts and also includes dependent claims specifying common salts such as d-threo-methylphenidate hydrochloride.
-
Are OTF strips and gummies outside the patent scope?
Claim 7 explicitly includes oral thin film (OTF), thin strips, gummies, chewables, and a broad set of oral and rectal dosage forms.
-
Is there a fixed blend ratio required for infringement?
No. The patent includes broad weight ratio coverage (5–95%) and also provides example ratios and discrete mg pairings that create multiple covered configurations.
-
What is the most important design-around lever?
The identity of the “compound” that is the conjugate of d-methylphenidate. Changing the conjugate structure is the most direct way to escape the independent claim.
References (APA)
- U.S. Patent 10,584,113. (n.d.). Claims as provided in prompt.
More… ↓
⤷ Start Trial
|
